Bionano Genomics IncNASDAQ:BNGONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4055
- TODAY'S CHANGE (%)-0.0145 (-3.4524%)
- Bid / Lots0.4053/ 10
- Ask / Lots0.4290/ 16
- Open / Previous Close0.4204 / 0.4200
- Day Range
- 52 Week Range
- Volume1,403,066
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Sep 10, 2024
DJ Bionano Genomics Cut to Neutral From Buy by BTIG, from 8:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 4, 2024
Bionano to Present at the H.C. Wainwright 26 Annual Global Investment Conference, from 8:00AM ET on Wednesday Sep 04, 2024 by Dow Jones
8:00AM ET on Wednesday Sep 04, 2024 by Dow Jones
Aug 28, 2024
DJ Bionano Genomics Cut to Sector Perform From Sector Outperform by Scotiabank, from 9:24AM ET on Wednesday Aug 28, 2024 by Dow Jones
9:24AM ET on Wednesday Aug 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bionano Genomics Inc | 34.9M | -0.1x | --- |
STRATA Skin Sciences Inc | 12.6M | -1.3x | --- |
Aamaxan Transport Group Inc | 1.6K | 0.0x | --- |
Cytosorbents Corp | 84.4M | -2.9x | --- |
LENSAR Inc | 51.7M | -4.0x | --- |
Dynatronics Corp | 1.0M | -0.2x | --- |
Company Information
Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
Contact Information
- Headquarters
- 9640 TOWNE CENTRE DRIVE 9640 TOWNE CENTRE DRIVESAN DIEGO, CA, United States 92121
- Phone
- 858-888-7600
- Fax
- 858-888-7601
Executives
- Independent Chairman of the Board
- David Barker
- President, Chief Executive Officer, Principal Financial Officer, Director
- R. Erik Holmlin
- Chief Financial Officer
- Gulsen Kama
- Chief Operating Officer
- Mark Oldakowski
- General Counsel, Secretary
- Jonathan Dixon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.9M |
|---|---|
Revenue (TTM) | $36.6M |
Shares Outstanding | 86.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-5.15 |
Book Value | $2.10 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -509.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
